Human sequencing sample tracking marker, and monitoring method and monitoring device for cross contamination of human sequencing sample

Abstract

The invention discloses a human sequencing sample tracking marker, and a monitoring method and a monitoring device for cross contamination of a human sequencing sample. The sequence of the marker is derived from Methanococcus jannaschii, and is not matched with a comparison result of a human reference genome sequence. The sequence of the human sequencing sample tracking marker is derived from Methanococcus jannaschii, and is not matched with the comparison result of the human reference genome sequence, so that the marker can be better tracked. Furthermore, through a double-quality control system in two aspects of the tracking marker and a cross contamination model, whether the sample is subjected to reverse exchange and cross contamination or not can be sensitively detected on the basis ofincreasing a small amount of cost and operation to the maximum extent, the sample is identified and subjected to quality control, and the accuracy of sequencing data is ensured.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a tracking marker for human sequencing samples, a monitoring method and a monitoring device for cross-contamination of human sequencing samples. Background technique [0002] Based on the dideoxy chain termination method (Sanger method) sequencing, next-generation sequencing technology (NGS) realizes multi-channel sequencing of multiple nucleic acid molecules at the same time, making sequencing toward high-throughput, low-cost, high-safety and commercial It has important applications in molecular biology, clinical medicine, disease screening and detection, etc., and provides a powerful platform for the study of pathogenic genes at the molecular level. But at the same time, next-generation sequencing technology needs to process a large number of samples at the same time, and perform standardized library construction operations in a unified manner. This process inevitably increases the...

AI Technical Summary

Problems solved by technology

[0008] Comparing sample information through bioinformatics to determine whether the sample contains biological information of other samples, this method increases a lot of work and cost, and prolongs the project cycle, affecting clinical medical disease monitoring and screening

In addition, the sensitivity and sensitivity of these methods have certain limitations. It is impossible to clearly identify the reversed and exchanged samples. It can only provide the complete situation of the confirmed samples, and it is impossible to judge whether the sequencing data corresponds to the original sample.

[0009] By marking the original sample, the marker can flow along with the original sample throughout the sequencing process, and the original sample can be determined according to the marker information detected in the sequencing data. This method adds a lot of complexity due to the complicated preparation process of most markers. It cannot be applied to the sequencing process on a large scale; and because the sequencing process involves many steps and the process is complicated, the amount of markers cannot be clearly controlled, so it is impossible to accurately measure cross-contamination between samples based on the quantitative relationship between the amount of markers. judgment

Images